- Current report filing (8-K)
October 20 2009 - 4:16PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
DATE OF REPORT (DATE OF EARLIEST
EVENT REPORTED):
October 20, 2009
GILEAD SCIENCES, INC.
(Exact name of registrant as specified in its
charter)
|
|
|
|
|
DELAWARE
|
|
0-19731
|
|
94-3047598
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
333 LAKESIDE DRIVE, FOSTER CITY, CALIFORNIA
(Address of principal executive offices)
94404
(Zip Code)
(650) 574-3000
(Registrants telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
SECTION 2 FINANCIAL INFORMATION
Item 2.02
|
Results of Operations and Financial Condition.
|
On October 20, 2009, Gilead Sciences, Inc., a Delaware corporation (Gilead), issued a press release announcing its financial results for the quarter ended September 30, 2009. A copy of the press release is filed as Exhibit 99.1 to
this report.
Non-GAAP net income attributable to Gilead and net income attributable to Gilead per diluted share for the three and nine months
ended September 30, 2009 are presented excluding the after-tax impact of acquisition-related transaction costs, amortization of inventory mark-up and amortization of purchased intangibles; restructuring expenses; and stock-based compensation
expenses, and have been adjusted for the application of Accounting Principles Board Opinion No. 25, Accounting for Stock Issued to Employees (APB 25), in computing non-GAAP dilutive securities. Non-GAAP net income attributable to
Gilead and net income attributable to Gilead per diluted share for the three months ended September 30, 2008 are presented excluding the after-tax impact of stock-based compensation expenses, and have been adjusted for the application of APB 25
in computing non-GAAP dilutive securities. Non-GAAP net income attributable to Gilead and net income attributable to Gilead per diluted share for the nine months ended September 30, 2008 are presented excluding the after-tax impact of
stock-based compensation expenses and purchased in-process research and development (R&D) expense, and have been adjusted for the application of APB 25 in computing non-GAAP dilutive securities. Non-GAAP R&D expenses for the three and nine
months ended September 30, 2009 are presented excluding the impact of restructuring expenses and stock-based compensation expenses. Non-GAAP selling, general and administrative (SG&A) expenses for the three and nine months ended
September 30, 2009 are presented excluding the impact of acquisition-related transaction costs, restructuring expenses and stock-based compensation expenses. Non-GAAP R&D expenses and SG&A expenses for the three and nine months ended
September 30, 2008 are presented excluding the impact of stock-based compensation expenses. Management believes this non-GAAP information is useful for investors, taken in conjunction with Gileads GAAP financial statements, because
management uses such information internally for its operating, budgeting and financial planning purposes. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of
Gileads operating results as reported under U.S. GAAP.
The information in this Form 8-K and the exhibit attached hereto shall not be
deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities under that section, nor shall it be deemed incorporated by reference in any
filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.
SECTION 9 FINANCIAL STATEMENTS AND EXHIBITS
Item 9.01
|
Financial Statements and Exhibits.
|
|
|
|
Exhibit
Number
|
|
Description
|
|
|
99.1
|
|
Press Release, issued by Gilead Sciences, Inc. on October 20, 2009
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
GILEAD SCIENCES, INC.
|
(Registrant)
|
|
/s/ Robin L. Washington
|
Robin L. Washington
|
Senior Vice President and Chief Financial Officer
|
Date: October 20, 2009
Exhibit Index
|
|
|
Exhibit
Number
|
|
Description
|
|
|
99.1
|
|
Press Release, issued by Gilead Sciences, Inc. on October 20, 2009
|
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Jun 2024 to Jul 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Jul 2023 to Jul 2024